Multiomics Solutions
Clinical & Diagnostics Laboratories
Advanced Multiomics Solutions for Clinical & Diagnostic Laboratories
At Signios Bio, we support Clinical & Diagnostic Labs with robust infrastructure and multiomics solutions to drive high-quality diagnostics and companion diagnostics. Leveraging decades of experience and advanced genomic assay capabilities, we provide laboratories with resources to develop, validate, and scale diagnostic assays tailored for precision healthcare.
With state-of-the-art sequencing platforms, we assist in the creation of reliable, high-sensitivity assays that meet rigorous quality standards.
Global Partner and Distribution Network
Bring your diagnostic solutions to market with our established network, reaching 35+ countries worldwide.
Real-World Evidence
As part of MedGenome, we have access to real-world evidence (RWE) from global research networks across the US, Europe, Asia, Africa, Middle East, and Latin America. This access enables us to work with our partners to uncover insights that can lead to new biomarkers and drug targets, ensuring that precision medicine is inclusive and effective for all.
Flexible Lab-in-the-Cloud Services
Complement your operations with LINC (Lab-in-the-Cloud) modular dry-lab services, providing seamless support for bioinformatics, LIMS, and other core needs.
Proven Impact
Developing and delivering a high-quality, cost-effective global CDx test
A top pharma company wanted to develop a cost-effective, end-to-end DNA-based lab-developed test for estimating homologous recombination deficiency (HRD) in ovarian tumor tissue samples. We completed the process from panel design to clinical validations within 10 months and set up a high-quality, cost-efficient HRD assay with the following performance metrics:
Concordance: 100%
PPA: 96.39%
NPA:98.3%
OPA: 97.05%
Optimizing, validating, and commercializing an assay
for NSCLC
A top pharma company had developed a qualitative digital PCR-based lung cancer panel to profile somatic mutations of NSCLC samples from both DNA and RNA in FFPE tissue. We collaborated with ChromaCode to optimize and clinically validate the assay using 350+ readily available clinical samples and achieved the following level of performance:
Accuracy: 98%
Sensitivity- 88%
Specificity- >99%
PPV- 97%
NPV- 98%
Resources
March 2025
|
Publication
Impact of switching antiplatelet therapy in acute coronary syndrome patients with different CYP2C19 phenotypes: insights from a single-center study
August 2024
|
Blog Post
Comprehensive cancer profiling with Illumina’s TSO 500 assay
April 2025
|
Whitepaper
OncoPeptTUME — A novel in-silico approach to model the tumor microenviroment and predict treatment efficacy and long-term survival benefits for immunotherapy applications